Antimykotika

  • Uwe Fricke

Zusammenfassung

Entsprechend der Bedeutung von Pilzinfektionen der Haut und Schleimhäute werden fast 90% der Antimykotika als Lokaltherapeutika verordnet. Zur Behandlung von Organmykosen steht dagegen nur ein begrenztes medikamentöses Arsenal zur Verfügung.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abeck D., Gruseck E., Korting H.C., Ring J. (1996): Onychomykose: Epidemiologie, Pathogenese, Klinik, Mikrobiologie und Therapie. Dtsch. Ärztebl. 93: A2027–2032.Google Scholar
  2. Amichai B., Grunwald M.H. (1998): Adverse drug reactions of the new oral antifungal agents - terbinafine, fluconazole, and itraconazole. Int. J. Dermatol. 37: 410–415.PubMedCrossRefGoogle Scholar
  3. Arca E., Tastan H. B., Akar A., Kurumlu Z., Gur A.R. (2002): An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J. Dermatol. Treat. 13: 3–9.CrossRefGoogle Scholar
  4. Ariyaratnam S., Thakker N.S., Sloan P., Thornhill M.H. (1997): Potentiation of warfarin anticoagulant activity by miconazole oral gel. Brit. Med. J. 314: 349.PubMedCrossRefGoogle Scholar
  5. Bennett M.L., Fleischer A. B., Loveless J.W., Feldman S.R. (2000): Oral griseofulvin remains the treatment of choice for tinea capitis in children. Ped. Dermatol. 17: 304–309.CrossRefGoogle Scholar
  6. Bernhardt H. (1998): Pilze im Darm–Normalflora oder Erreger ? Z. ärztl. Fortbild. Qual. sich. (ZaeFQ) 92: 154–156.Google Scholar
  7. Chu A.C. (1984): Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor. Dermatologica 169 (Suppl. 1): 81–86.PubMedCrossRefGoogle Scholar
  8. Crawford F., Hart R., Bell-Syer S., Torgerson D., Young P., Russell I. (2000): Topical treatments for fungal infections of the skin and nails of the foot (Cochrane Review). In: The Cochrane Library, Issue 1, 2000. Oxford: Update Software.Google Scholar
  9. Dinnendahl V., Fricke U. (Hrsg.) (2002): Arzneistoff-Profile. Basisinformation über arzneiliche Wirkstoffe. Stammlieferung 1982 mit 1. bis 17. Ergänzungslieferung 2002, Govi-Verlag, Eschborn.Google Scholar
  10. Evans E.G.V., Sigurgeirsson B. for the LION study group (1999): Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Brit. Med. J. 318: 1031–1035.PubMedCrossRefGoogle Scholar
  11. Friedlander S.F., Suarez S. (1998): Pediatric antifungal therapy. Ped. Dermatol. 16: 527–537.Google Scholar
  12. Friedlander S.F. (2000): The optimal therapy for tinea capitis. Ped. Dermatol. 17: 325–326.CrossRefGoogle Scholar
  13. Goa K.L., Barradell L. B. (1995): Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50: 658–690.PubMedCrossRefGoogle Scholar
  14. Grant S.M., Clissold S.P. (1989): Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37: 310–344.Google Scholar
  15. Grant S.M., Clissold S.P. (1990): Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39: 877–916.CrossRefGoogle Scholar
  16. Gupta A.K. (2002): Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J. Am. Podiatr. Med. Assoc. 92: 272–286.PubMedGoogle Scholar
  17. Gupta A.K., Sauder D.N., Shear N.H. (1994): Antifungal agents: An overview. Part I+II. J. Am. Acad. Dermatol. 30: 677–698 und 911–933.CrossRefGoogle Scholar
  18. Gupta A.K., Gonder J.R., Shear N.H., Dilworth G.R. (1996): The development of green vision in association with terbinafine therapy. Arch. Dermatol. 132: 845–846.Google Scholar
  19. Gupta A.K., Einarson T.R., Summerbell R.C., Shear N.H. (1998): An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 55: 645–674.Google Scholar
  20. Gupta A.K., Shear N.H. (1999): The new oral antifungal agents for onychomycosis of the toenails. J. Eur. Acad. Dermatol. Venereol. 13: 1–13.PubMedCrossRefGoogle Scholar
  21. Gupta A.K., Lynde C.W., Konnikov N. (2001a): Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. 44: 485–491.PubMedCrossRefGoogle Scholar
  22. Gupta A.K., Lambert J., Revuz J., Shear N. (2001b): Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur. J. Dermatol. 11: 6–10.PubMedGoogle Scholar
  23. Haneke E., Tausch I., Bräutigam M., Weidinger G., Welzel D. (1995): Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J. Am. Acad. Dermatol. 32: 72–77.PubMedCrossRefGoogle Scholar
  24. Haria M., Bryson H.M. (1995): Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 49: 103–120.PubMedCrossRefGoogle Scholar
  25. Haria M., Bryson H.M., Goa K.L. (1996): Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51: 585–620.PubMedCrossRefGoogle Scholar
  26. Hart R., Bell-Syer S.E.M., Crawford E, Torgerson D.J., Young P., Russell I. (1999): Systematic review of topical treatments for fungal infections of the skin and nails of the feet. Brit. Med. J. 319: 79–82.PubMedCrossRefGoogle Scholar
  27. Havu V., Heikkila H., Kuokkanen K., Rantanen T., Saari S., Stubb S., Suhonen R., Turjanmaa K. (2000): A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br. J. Dermatol. 142: 97–102.PubMedCrossRefGoogle Scholar
  28. Hay R.J. (1992): Treatment of dermatomycoses and onychomycoses–state of the art. Clin. Exp. Dermatol. 17 (Suppl. 1): 2–5.PubMedCrossRefGoogle Scholar
  29. Hecker D. (1997): Current trends in onychomycosis therapy: A literature review. Mount Sinai J. Med. 64: 399–405.Google Scholar
  30. Higgins E.M., Fuller L.C., Smith C.H. (2000): Guidelines for the management of tinea capitis. Br. J. Dermatol. 143: 53–58.PubMedCrossRefGoogle Scholar
  31. Hornstein O.P., Nürnberg E. (Hrsg.) (1985): Externe Therapie von Hautkrankheiten: Pharmazeutische und medizinische Praxis. Georg Thieme Verlag, Stuttgart, New York, pp. 304–315.Google Scholar
  32. Howard R.M., Frieden I.J. (1999): Dermatophyte infections in children. Adv. Pediatr. Infect. Dis. 14: 73–107.PubMedGoogle Scholar
  33. Katsambas A., Rigopoulos D., Antoniou C., Zachari A., Fragouli E., Stratigos J. (1996): Econazole 1% shampoo versus selenium in the treatment of tinea versicolor: A single-blind randomized clinical study. Int. J. Dermatol. 35: 667–668.PubMedCrossRefGoogle Scholar
  34. Kauffman C.A., Carver P.L. (1997): Antifungal agents in the 1990s. Current status and future development. Drugs 53: 539–549.PubMedCrossRefGoogle Scholar
  35. Knoke M. (1998): Pilze im Orointestinaltrakt und ihre wissenschaftlich begründete Stellung. Z. ärztl. Fortbild. Qual.sich. (ZaeFQ) 92: 157–162.Google Scholar
  36. Korting H.C. (1995): Dermatotherapie. Springer-Verlag, Berlin, Heidelberg, New York.Google Scholar
  37. Male O. (1981): Medizinische Mykologie für die Praxis. Georg Thieme Verlag, Stuttgart, New York.Google Scholar
  38. McClellan K.J., Wiseman L.R., Markham A. (1999): Terbinafine. An update of its use in superficial mycoses. Drugs 58: 179–202.PubMedCrossRefGoogle Scholar
  39. Merk H.F. (1993): Antimykotika. Teil I und II. Hautarzt 44: 191–199 und 257–267.Google Scholar
  40. Müller J. (1993): Besonderheiten von Pilz-Keimträgern als Dauerausscheider. Zbl. Hyg. 194: 162–172.Google Scholar
  41. Niewerth M., Korting H.C. (1999): Management of onychomycoses. Drugs 58: 283–296.PubMedCrossRefGoogle Scholar
  42. Niewerth M., Korting H.C. (2000): The use of systemic antimycotics in dermatotherapy. Eur. J. Dermatol. 10: 155–160.PubMedGoogle Scholar
  43. Pierard G.E., Arrese J.E., Pierard-Franchimont C. (1996): Treatment and prophylaxis of tinea infections. Drugs 52: 209–224.PubMedCrossRefGoogle Scholar
  44. Powderly W.G., Mayer K.H., Perfect J.R. (1999): Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res. Hum. Retroviruses 15: 1405–1412.PubMedCrossRefGoogle Scholar
  45. Quintanar-Guerrero D., Ganem-Quintanar A., Tapia-Olguin P., Kaliar Y.N., Buri P. (1998): The effect of keratolytic agents on the permeability of three imidazole antimycotic drugs through the human nail. Drug Dev. Ind. Pharm. 24: 685–690.PubMedCrossRefGoogle Scholar
  46. Ring J., Fröhlich H.H. (1985): Wirkstoffe in der dermatologischen Therapie, 2. Aufl. Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, pp. 133–136 und 211–213.Google Scholar
  47. Roberts D.T. (1994): Oral therapeutic agents in fungal nail disease. J. Am. Acad. Dermatol. 31: S78 - S81.PubMedCrossRefGoogle Scholar
  48. Rösch W. (1996): Pilze im Stuhl, Pilze im Darm–therapeutische Konsequenzen? Versicherungsmedizin 48: 215–217.PubMedGoogle Scholar
  49. Schäfer-Korting M., Blechschmidt J. Korting H.C. (1996): Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Mycoses 39: 329–339.PubMedCrossRefGoogle Scholar
  50. Scheurlen M. (1996): Pathogenität von Pilzen im Darm–Stand der Diskussion. Fortschr. Med. 114: 319–321.PubMedGoogle Scholar
  51. Scholz H., Schwabe U. (Hrsg.) (2000): Taschenbuch der Arzneibehandlung. Angewandte Pharmakologie, 12. Aufl. Urban& Fischer München, Jena.Google Scholar
  52. Seebacher C. (1996): Mykophobie–eine neue Krankheit? Mycoses 39 (Suppl. 1): 30–32.PubMedCrossRefGoogle Scholar
  53. Sigurgeirsson B., Olafsson J.H., Steinsson J. B., Paul C., Billstein S., Evans E.G.V. (2002): Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis. Arch. Dermatol. 138: 353–357.PubMedCrossRefGoogle Scholar
  54. Steigleder G.K. (1993): Therapie der Hautkrankheiten, 4. Aufl. Georg Thieme Verlag, Stuttgart, New York.Google Scholar
  55. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. (2000): Effects of the antifungal agents on oxidative drug metabolism. Clin. Pharmacokinet. 38: 111–180.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Uwe Fricke

There are no affiliations available

Personalised recommendations